Careers
Contact
Pharmacovigilance
Whistleblowing
Foundation
us
Global
it
us
Dompé Global
Dompé Italy
Dompé China
Foundation
Exscalate
Who We Are
About Us
Our Heritage
Management Team
Responsibility
Environment, Quality and Safety
Ethics and Compliance
Grants & Donations
Where We Are
Science
Nerve Growth Factor
NETosis
Reparixin
Ladarixin
Pipeline
Publications
Exscalate
Therapeutics
Ophthalmics
Neurotrophic Keratitis
Manufacturing
Production Plant
Biotech
Pharma
People & Culture
Media
Press Releases
Dompé in the News
Stories
Media Library
Search
Search
Paolo Pozzilli, MD: Ladarixin, a CXCR1/2 inhibitor, in Type 1 Diabetes
15/06/2020
Published in:
HCP Live
Find out more